ranibizumab
AssetDeviceAlso Port Delivery System With Ranibizumab, LUCENTIS, Ranibizumab Injection
Sustained-release ocular implant formulation of ranibizumab inhibiting VEGF-A
- Stage
- Phase 3
- Modality
- Device
- Target
- VEGFA
- Indications
- 6
- Trials
- 2
- Developers
- 2
Indications
6Neovascular age-related macular degeneration
Phase 3RECRUITINGNCT04853251clinicaltrials.gov7 Oct 2026
Branch retinal vein occlusion
Human trialsACTIVE_NOT_RECRUITINGNCT05476926clinicaltrials.gov7 Oct 2026
Central retinal vein occlusion
Human trialsACTIVE_NOT_RECRUITINGNCT05476926clinicaltrials.gov7 Oct 2026
3 more
- Targets and what it contains1
- Owner and partners2
- Trials2
- Evidence for its targets1
- Competitors7
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources